Cystic Fibrosis  >>  ciprofloxacin (Q3939)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ciprofloxacin (Q3939) / Bayer, Novartis
NCT00910351: Cipro Inhaler for Cystic Fibrosis Children Ages 6-12

Completed
1
19
US
Ciprofloxacin (Cipro, BAYQ3939)
Bayer
Pseudomonas Infection
10/10
10/10
2007-002912-24: Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 years

Completed
1
16
Europe
Ciprofloxacin, BAY q 3939,
Bayer HealthCare AG
long term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosis
 
07/08

Download Options